Pediatrix Medical Group, Inc. (NYSE:MD - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $26.61, but opened at $25.33. Pediatrix Medical Group shares last traded at $26.4640, with a volume of 14,790 shares changing hands.
Wall Street Analysts Forecast Growth
MD has been the topic of a number of recent analyst reports. Weiss Ratings cut Pediatrix Medical Group from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 25th. Mizuho set a $24.00 price target on shares of Pediatrix Medical Group in a research report on Friday, May 8th. UBS Group lifted their price objective on shares of Pediatrix Medical Group from $25.00 to $28.00 and gave the stock a "neutral" rating in a research note on Thursday, August 6th. Jefferies Financial Group cut shares of Pediatrix Medical Group from a "buy" rating to a "hold" rating and boosted their price objective for the company from $27.00 to $28.00 in a report on Wednesday, August 19th. Finally, Truist Financial upped their target price on shares of Pediatrix Medical Group from $23.00 to $28.00 and gave the company a "hold" rating in a research note on Tuesday, July 14th. Seven investment analysts have rated the stock with a Hold rating, According to MarketBeat, Pediatrix Medical Group currently has a consensus rating of "Hold" and an average price target of $25.00.
View Our Latest Analysis on MD
Pediatrix Medical Group Stock Down 1.7%
The firm has a fifty day simple moving average of $26.06 and a 200-day simple moving average of $23.19. The company has a market capitalization of $2.13 billion, a P/E ratio of 12.52 and a beta of 0.66. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.45.
Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a return on equity of 20.05% and a net margin of 8.96%.The business had revenue of $487.78 million for the quarter, compared to analysts' expectations of $478.49 million. During the same quarter in the previous year, the business posted $0.53 EPS. Pediatrix Medical Group's revenue for the quarter was up 4.1% on a year-over-year basis. On average, equities research analysts expect that Pediatrix Medical Group, Inc. will post 2.17 EPS for the current fiscal year.
Institutional Investors Weigh In On Pediatrix Medical Group
Several large investors have recently made changes to their positions in MD. Global Retirement Partners LLC lifted its position in Pediatrix Medical Group by 68,250.0% in the 4th quarter. Global Retirement Partners LLC now owns 1,367 shares of the company's stock valued at $29,000 after acquiring an additional 1,365 shares in the last quarter. Transamerica Financial Advisors LLC bought a new position in Pediatrix Medical Group during the 4th quarter worth about $30,000. Eurizon Capital SGR S.p.A. bought a new position in Pediatrix Medical Group during the 4th quarter worth about $33,000. Nykredit A S acquired a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at about $35,000. Finally, TD Private Client Wealth LLC acquired a new stake in shares of Pediatrix Medical Group in the 4th quarter valued at about $39,000. Institutional investors own 97.71% of the company's stock.
About Pediatrix Medical Group
(
Get Free Report)
Pediatrix Medical Group, Inc NYSE: MD is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.
Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Pediatrix Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pediatrix Medical Group wasn't on the list.
While Pediatrix Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.